PHARMA News & Analysis

All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far. 

Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.

Morningstar thinks these companies are well positioned to benefit from one of five key trends during the next decade, writes Susan Dziubinski.

We expect most US adults will be vaccinated in the first half of 2021, writes Morningstar healthcare strategist Karen Andersen.

Morningstar had forecast big losses for the drugmaker, which has been dropped from the ASX 200.

Consumer stock Breville and listed property firm Charter Hall were among the highest gainers after delivering results, while Mayne Pharma and Seven...

Morningstar's Karen Andersen explains how environmental, social and governance issues affect Big Pharma and biotech companies.

The legalisation of cannabis in Canada has boosted an industry that Morningstar forecasts will grow by nine times through 2030

The specialty drug-maker exceeded analysts' expectations on an adjusted basis, despite posting a full-year loss of $133.98 million.

These companies are each trading at prices substantially below Morningstar analysts' fair value estimates and with projected earnings-per-share...